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Objective: Oxidative damage and inflammation are believed to play an important
role in postoperative complications after cardiopulmonary bypass. During bypass, a
prime solution with a high antioxidant capacity may reduce the oxidative damage
and inflammation. We investigated total antioxidant capacity and individual scav-
engers during the preparation of 2 different prime solutions.
Methods: The prime solutions were prepared with either pasteurized human albu-
min or fresh frozen plasma. The total antioxidant capacity was measured with the
total radical antioxidant parameter assay and with the ferric-reducing ability of plas-
ma assay. The individual scavengers vitamin C, sulfhydryl groups, uric acid, and
total protein were measured before, during, and after the prime preparation.
Malondialdehyde was measured as a parameter for lipid peroxidation.
Results: Neither prime solution showed a total radical antioxidant parameter value.
The ferric-reducing ability of plasma value of prime solutions was lower than that
of undiluted human albumin or fresh frozen plasma. Addition of mannitol did not
increase the ferric-reducing ability of plasma value. Vitamin C was only found in
the fresh frozen plasma prime. Both prime solutions contained sulfhydryl groups
and uric acid in low concentrations. During ultrafiltration, low-molecular-weight
antioxidants were lost into the ultrafiltrate.
Conclusions: We showed that prime solutions based on either albumin or fresh
frozen plasma had very low antioxidant capacity and that ultrafiltration of the prime
solution further lowers this capacity. A prime solution with a low antioxidant capac-
ity may increase oxidative stress in neonates undergoing cardiopulmonary bypass.
Oxidative damage and inflammation are believed to be importantcauses of morbidity related to cardiopulmonary bypass (CPB),which is high, especially in small infants.1 During CPB, pro-oxidative substances, such as nonprotein-bound iron, are releasedwhile the plasma antioxidant capacity decreases, resulting inexcess accumulation of reactive oxygen species.2 This may be
especially important in neonates who, compared with more mature patients, already
have low plasma iron-binding capacity and poor antioxidant defenses, which
decrease even further after CPB.3,4 This may cause oxidative stress, direct tissue
damage, and multiorgan failure. Moreover, oxidative stress may upregulate the
inflammatory response and initiate a vicious oxidative circle.1,5 Enhancing the
antioxidant capacity of patients during CPB could limit the direct oxidative tissue
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damage and modulate the undesired inflammatory response.
The prime solution of the CPB system can substantially
affect the plasma antioxidant capacity because of the high
ratio between prime and circulating volume of neonatal
patients. As previously reported, even transfusion of a rela-
tively small volume of fluid with a low antioxidant capacity
decreases the ability of plasma of neonates to catabolize
reactive oxygen species.6 Thus, a large prime volume with a
low antioxidant capacity may dramatically decrease the
antioxidant capacity of neonates undergoing CPB. On the
other hand, a supplementation of the prime solution with
antioxidants could decrease the negative effect of the dilu-
tion and limit the oxidative stress during CPB.7-9
Albumin-based prime solution, which is routinely used
in our institution, may have a lower antioxidant capacity
than an alternative prime solution based on fresh frozen
plasma (FFP). Ultrafiltration during prime preparation
could change the antioxidant status of prime solution by
means of removal of water-soluble antioxidants or pro-
oxidative substances, such as nonprotein-bound iron.
Therefore, we investigated the total antioxidant capacity, as
well as that of selected individual antioxidants, during the
preparation of these 2 different prime solutions.
Materials and Methods
This in vitro study was approved by the Scientific Committees of
the Department of Pediatrics and the Department of Thoracic
Surgery. Preserved packed red blood cells (RBCs; stored for <5
days) and FFP were delivered by our blood bank. RBCs were pre-
served and stored in saline, adenosine, glucose, and mannitol
(SAGM) solution. FFP contains citrate, which is used as an anti-
coagulant during donor blood preparation. Informed consent of the
donors was obtained. Twenty percent human albumin solution was
obtained from CLB (Amsterdam, The Netherlands). This is a plas-
ma-derived product prepared by means of ethanol fractionation
and pasteurization (10 hours at 60°C). It contains mainly albumin
(95%), but other proteins are also present, such as prealbumin and
haptoglobin.
Prime Composition and Preparation
Prime composition and preparation are shown in Figure 1. Two dif-
ferent prime solutions on the basis of either albumin or FFP were
prepared, each on 5 separate occasions. At room temperature, the
cardiotomy reservoir of a Dideco Lilliput 901 CPB system
(Dideco, Mirandola, Italy) was filled with 500 mL of Ringer’s
solution with 1500 IU of heparin and either 100 mL of 20% human
albumin (ALB prime) or 100 mL of FFP (FFP prime). The oxy-
genator was filled, and after 15 minutes of circulation, 100 mL of
packed RBCs were added to the clear ALB or FFP prime. After 5
minutes of circulation of this RBC prime, ultrafiltration was per-
formed with a Minntech Hemocor HPH 400 (Minntech Corp,
Minneapolis, Minn) to reduce the prime volume to 350 mL. Then
1.0 g of mannitol and 4.0 mL of 8.4% sodium bicarbonate were
added. Five minutes later, the temperature of the prime was
increased to 32°C for 60 minutes. (In a clinical situation, this
decreases the temperature difference between prime and patient.)
The flow of the prime and the air flow (fraction of inspired oxygen
= 0.21) was 0.50 L/min. The flow through the ultrafilter was 0.20
L/min, with a constant pressure of 75 mm Hg.
Samples
Samples of undiluted albumin solution and FFP were collected.
Samples (3 mL) of the prime at various stages of its preparation
and one sample of ultrafiltrate were collected, protected from light,
immediately cooled, and transported to the laboratory to be cen-
trifuged (4°C for 5 minutes at 2000 rpm). For measurements of vit-
amin C, the samples were stabilized with metaphosphoric acid and
deferoxamine mesylate (Desferal). The samples were frozen until
analysis (–80°C under argon). Preliminary studies showed that val-
ues did not change during storage.3
Cardiopulmonary Support and Physiology Molicki et al
Figure 1. Composition, preparation, and sampling of the primes. 1, Clear prime; 2, RBC prime before ultrafiltration;
3, RBC prime after ultrafiltration; 4, RBC prime after mannitol and bicarbonate; 5, 6, and 7, RBC prime after 20, 40,
and 60 minutes, respectively, at a temperature of 32°C. Sample of ultrafiltrate was collected at the end of ultrafil-
tration.
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Laboratory Measurements
The total antioxidant capacity was measured with 2 different
methods.
The total radical antioxidant parameter (TRAP) assay measures
the ability of the investigated sample to inhibit peroxidation of the tar-
get lipid (linoleic acid) induced by peroxyl radicals. This lipid perox-
idation is measured by means of oxygen consumption with an oxy-
gen electrode. Extent of the inhibition, if any, is quantified by using
Trolox (water-soluble analog of vitamin E) as a calibrator.6,10
The ferric-reducing ability of plasma (FRAP) assay measures
the capacity of the sample to reduce ferric ion (Fe3+) to the ferrous
form (Fe2+). This reduction can be measured by means of spec-
trophotometry because ferrous ions bind to tripyridyltriazin to
form a blue-colored complex. The results of the assay are quanti-
tated by use of a solution containing ferrous ions in a known con-
centration as a calibrator.11
Individual Antioxidants
Vitamin C was measured with high-performance liquid chro-
matography, as previously described.12-14 This method measures
total ascorbic acid and its oxidized form, and reduced ascorbic acid
is calculated by subtraction. Knowing the concentration of vitamin
C and the exact (corrected for sampling) volume of prime, we cal-
culated the total amount of vitamin C in the prime. Sulfhydryl
groups were determined by spectrophotometry, as previously
described.15 Uric acid, total protein, and albumin were measured
by means of an automatic analyzer (Hitachi 747; Roche
Diagnostics GMBH, Mannheim, Germany).
Lipid Peroxidation Product
Malonyldialdehyde (MDA) was measured by means of high-per-
formance liquid chromatography, as adapted and modified from
the previous study.16
Statistics
All results are reported as means ± standard deviation (SD).
Differences between oxidized/total ratio of vitamin C before and
after FFP prime preparation were tested by using the t test for
paired samples. Differences between means of the amount of
vitamin C present in the prime in different samples were mea-
sured by 1-way analysis of variance. Differences between the
amount of vitamin C present in FFP prime before and after ultra-
filtration were tested by using a paired t test. Correlation
between free hemoglobin/heme concentration and oxidized/total
vitamin C ratio was tested with the Pearson method by the 2-
tailed test of significance.
Results
The samples from one FFP prime preparation became
hemolytic during centrifugation. After box-plot analysis, we
excluded the results of these samples from FRAP and vita-
min C statistic analysis.
Total Antioxidant Capacity
ALB prime. The TRAP assay detected no antioxidant
capacity in either undiluted albumin solution or in the sam-
ples of the prime. The FRAP value in the undiluted albumin
solution was 1813.7 µmol/L. In the clear prime, the FRAP
value was 651.6 ± 190.8 µmol/L and increased during the
procedure, reaching a value of 901.2 ± 255.9 µmol/L. The
ultrafiltrate had a FRAP value of 542.5 ± 225.3 µmol/L
(Figure 2).
FFP prime. The TRAP value of undiluted FFP was
752.75 ± 40.1 µmol/L; however, the assay detected no
antioxidant capacity in the samples of the prime. The FRAP
Figure 2. Measurement of FRAP assay (mean ± SD; circulation 6 excluded). Sampling is described in the legend
for Figure 1. UF, Ultrafiltration.
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Figure 3. A, Individual vitamin C concentrations (in micromoles per liter) during the preparation of FFP prime (circu-
lation 6 excluded). Sampling is described in the legend for Figure 1. Notice the large variability in concentrations
between the different circulations (CIR) and especially the concentrations in the ultrafiltrates (UF). B, The total load
(mean) of vitamin C in milligrams during the preparation of the FFP primes (circulation 6 excluded). Sampling is
described in the legend for Figure 1. Notice the loss of vitamin C during the whole preparation (paired t test: P = .017
for sample 1 and sample 7; before and after the preparation, respectively) and especially during ultrafiltration (paired
t test: P = .019 for sample 2 and sample 3; before and after ultrafiltration, respectively). C, Measurements of oxi-
dized/total ratio vitamin C (circulation 6 excluded). Sampling is described in the legend for Figure 1 (paired t test: P =
.006 for sample 1 and sample 7).
A
B
C
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value in the undiluted FFP was 2841.5 ± 703.2 µmol/L. In
the clear prime the FRAP value was 486.9 ± 49.8 µmol/L
and increased during the procedure, reaching a value of
635.3 ± 36.4 µmol/L. The ultrafiltrate had a FRAP value of
472.1 ± 17.4 µmol/L (Figure 2). Although there was a dif-
ference in FRAP values between the ALB and the FFP
primes after the preparation, this difference was not signifi-
cant (P = .08).
Vitamin C
ALB prime. No vitamin C was detected.
FFP prime. FFP prime contained vitamin C (Figure 3,
A-C). Its mean concentration in the clear prime was 8.86 ±
3.15 µmol/L, ranging from 6.07 to 11.80 µmol/L and
decreasing to 4.64 ± 1.27 µmol/L after 20 minutes of circu-
lation of the prime at 32°C and to 2.78 ± 0.37 µmol/L after
completion of the procedure (analysis of variance, P =
.0035). In the ultrafiltrates, vitamin C was found in the same
concentration as in the primes. Because of this, the total
amount of vitamin C in the prime decreased during ultrafil-
tration from 1.04 ± 0.40 mg to 0.57 ± 0.20 mg. During the
circulation of the prime at 32°C, the total amount of vitamin
C decreased even further to 0.18 ± 0.03 mg after completion
of the procedure. The oxidized/total vitamin C ratio
increased from 0.11 ± 0.07 in the clear prime to 0.17 ± 0.04
after completion of the procedure. The ratio was positively
correlated with free hemoglobin/heme concentrations in the
primes (r = 0.88-0.83 and 0.83-0.69, respectively).
Interestingly, in the hemolytic samples the ratio increased to
0.49 after the preparation and was strongly correlated with
concentrations of heme (r = 0.89 and P = .003, data not
shown).
Sulfhydryl Groups
Sulfyhdryl data are shown in Figure 4.
ALB prime. Clear prime contained sulfhydryl groups at
a concentration of 203.4 ± 0.9 µmol/L. This concentration
did not change after addition of RBCs but increased after
ultrafiltration to 315.8 ± 10.9 µmol/L and remained stable
until completion of the preparation. Ultrafiltrate contained
no sulfhydryl group. Calculated sulfhydryl/total protein
ratio was 4.74 ± 0.20 in clear prime and 5.53 ± 0.77 after
completion of prime preparation.
FFP prime. Clear prime contained sulfhydryl groups at
a concentration of 70.1 ± 12.2 µmol/L. This concentration
did not change after adding RBCs but increased slightly
after ultrafiltration to 111.8 ± 15.2 µmol/L and remained
stable until completion of the preparation. The ultrafiltrate
contained no sulfhydryl group. Calculated sulfhydryl/total
protein ratio was 5.70 ± 1.19 in clear prime and 5.77 ± 0.64
after completion of prime preparation.
Uric Acid
ALB prime. Clear prime contained no uric acid. After
adding RBCs, uric acid was detectable at a concentration of
0.01 ± less than 0.001 mmol/L (mean ± SD) and increased
to 0.02 ± 0.01 mmol/L at the end of preparation. In ultrafil-
trate, uric acid was found at a concentration of 0.01 ± 0.01
mmol/L.
FFP prime. Clear prime contained uric acid at a concen-
tration of 0.04 ± less than 0.001 mmol/L and remained sta-
ble until the temperature increased and then increased to
0.06 ± 0.01 mmol/L after completion of prime preparation.
In the ultrafiltrate, uric acid was found in the concentration
of 0.04 ± less than 0.001 mmol/L.
Figure 4. Measurements of sulfhydryl (SH) groups (mean ± SD). Sampling is described in the legend for Figure 1.
No sulfhydryl groups were present in the ultrafiltrate.
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Total Protein and Albumin
ALB prime. Clear prime contained 42 ± 1.8 g/L protein
(consisting of albumin, although we did not exclude traces
of other proteins). Addition of RBCs slightly decreased the
concentration of protein, and ultrafiltration increased it to 62
± 2 g/L. After that, the protein content remained stable.
FFP prime. Clear prime contained 12 ± 0.9 g/L protein.
Adding RBCs slightly decreased the concentration of pro-
tein, and ultrafiltration increased it to 18.4 ± 0.9 g/L. After
that, the protein content remained stable. Protein in all FFP
samples consisted of 55% to 60% albumin.
Malonyldialdehyde
ALB prime. Clear prime contained MDA at a concentra-
tion of 0.43 ± 0.05 µmol/L. This concentration increased
slightly after adding RBCs (0.47 ± 0.1 µmol/L) and much
more after ultrafiltration to 0.66 ± 0.08 µmol/L and slightly
decreased during circulation at 32°C, reaching 0.62 ± 0.1
µmol/L after completion of the preparation. The ultrafiltrate
contained MDA at a concentration of 0.13 ± 0.02 µmol/L.
FFP prime. Clear prime contained MDA at a concentra-
tion of 0.19 ± 0.07 µmol/L. This concentration increased
slightly after adding RBCs to 0.28 ± 0.02 µmol/L and after
ultrafiltration to 0.31 ± 0.05 µmol/L and remained stable
until completion of the preparation. Ultrafiltrate contained
MDA at a concentration of 0.12 ± 0.04 µmol/L.
Discussion
CPB was reported to completely deplete the total antioxi-
dant capacity in neonates.4 However, a possible effect of the
composition of prime solution and its dilution effect on
plasma of patients was not discussed. In our experience,
even transfusion of a relatively small volume of pasteurized
plasma protein solution, a plasma-derived product with no
TRAP value, can decrease the antioxidant capacity of plas-
ma of neonates.6 The ratio between the prime volume and
the circulating volume of neonates is much higher than dur-
ing transfusion. As a result, prime solution with a low
antioxidant capacity could substantially decrease the ability
of these patients to metabolize reactive oxygen species. We
therefore studied the antioxidant capacity of 2 different
prime solutions.
We showed that both ALB and FFP prime solutions have
a low total antioxidant capacity. TRAP assay revealed no
antioxidant capacity in ALB prime, reflecting the fact that
human albumin solution has no TRAP value. This is proba-
bly because of aggressive processing of donor plasma caus-
ing damage or loss of antioxidants during manufacturing of
this plasma-derived product. The TRAP value of FFP prime
was also undetectable, probably as a result of dilution of
donor plasma, which had a normal TRAP value. The FRAP
value of human albumin solution was originally much lower
than that of FFP. However, the FRAP value of the clear ALB
prime was, surprisingly, slightly higher than that of FFP
prime. This suggests a different effect of dilution of human
albumin solution and FFP or an interaction with heparin.
Heparin is believed to have an antioxidant activity; howev-
er, its exact mechanism is not clear.17 Moreover, measure-
ment of total antioxidant capacity can be influenced by
heparinization of samples, giving higher apparent results.18
In FFP prime this effect of heparin can be lower because of
its binding to antithrombin III in donor plasma. In ALB
prime, unbound heparin can possibly increase the results of
the FRAP assay. Relatively high FRAP values of ultrafil-
trates of both primes suggest that this assay mainly mea-
sures the effect of low-molecular-weight antioxidants.
Interestingly, the hemolytic samples had very high FRAP
values. Mannitol, which is widely used as an important
hydroxyl radical scavenger, did not improve the total antiox-
idant capacity of the prime solutions.19,20
For further insight into the antioxidant properties of the
prime solutions, we also investigated a few selected antiox-
idants during the prime preparation.
Vitamin C, an important secondary antioxidant, was not
detected in ALB prime, probably because of its loss during
the production process of albumin solution. There was a large
variability in vitamin C concentrations between the different
preparations of the FFP prime, probably because of donor
variability. These differences became small after the prime
preparation. The concentrations remained stable after adding
RBCs, bicarbonate, and mannitol but decreased sharply dur-
ing circulation at 32°C. RBCs rapidly take up oxidized vita-
min C and slowly release the reduced form of vitamin C.21
This active uptake of vitamin C may explain the decrease of
Cardiopulmonary Support and Physiology Molicki et al
TABLE 1. Plasma concentrations of the various plasma antioxidants compared with the concentrations in the prime solu-
tions after the prime preparation procedure
Term babies Adults ALB prime FFP prime
Uric acid (µmol/L) 317 ± 66 285 ± 55 0.02 ± 0.01 0.06 ± 0.01
Vitamin C (µmol/L) 130 ± 55 62 ± 16 ND 2.78 ± 0.37
Sulfhydryl groups (µmol/L) 422 ± 80 496 ± 57 315.8 ± 10.9 111.8 ± 15.2
Data are presented as means ± standard deviation. Data for term babies and adults are adapted from reference 28. FFP, fresh frozen plasma; ND, not
detectable.
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concentration of total vitamin C. Concomitantly, with a
decreasing concentration of vitamin C, its oxidized/total ratio
increased, suggesting a rise in oxidation or less effective recy-
cling of oxidized vitamin C. Oxidation of vitamin C can be
explained by interaction with pro-oxidative free hemoglo-
bin/heme present in the prime. Glutathione plays a crucial
role in the recycling of oxidized vitamin C.22 The ability of
RBCs to maintain glutathione is diminished during the prime
preparation (unpublished data). This can result in decreased
recycling of vitamin C and increasing of its oxidized/total
ratio in the prime solution. Ultrafiltration did not change the
concentration of vitamin C; however, its total amount in the
prime decreased because of loss into the ultrafiltrate.
Uric acid is the most important antioxidant and contribu-
tor to the TRAP value of human plasma.6,10 Both primes
contained very low concentrations of uric acid. However, it
was much higher in FFP prime than in ALB prime. Uric acid
in FFP prime originated from donor plasma, and its low
concentration is an effect of its dilution. Clear ALB prime
contained no uric acid, and RBCs added to the prime con-
tributed to its minimal concentration thereafter. The concen-
tration of uric acid in ultrafiltrate was the same as in the
primes, indicating that this small molecule was (similarly to
vitamin C) freely filtered out during ultrafiltration.
Proteins used to maintain the colloid osmotic pressure
during CPB (especially albumin) can contribute to the
antioxidant capacity of the primes. Albumin binds pro-oxida-
tive heme and transition metals, whereas its sulfhydryl and,
as recently reported, hydroxyl groups can act secondarily
(eg, scavengers and antioxidants).23,24 Moreover, human
albumin solution also contains some haptoglobin, which
binds potentially pro-oxidative hemoglobin.25 ALB prime
has higher protein (albumin) contents than FFP prime, which
is a logical consequence of their composition. High albumin
concentration in ALB prime could improve its antioxidant
capacity.23 Plasma sulfhydryl groups are mainly present in
the cysteine components of proteins and in low concentra-
tions in glutathione. However, the sulfhydryl/protein ratio
was lower in ALB prime than in FFP prime, and we found
free heme and nonprotein-bound iron in ALB prime (unpub-
lished data). This can be explained by oxidation of
sulfhydryl groups as a result of plasma processing during the
production of albumin solution.
MDA is a product of lipid peroxidation but can also
attack proteins and DNA.26 It was present in both clear
primes in very low concentrations because of the effect of
dilution of donor plasma and albumin solution.
Concentrations of MDA in ultrafiltrate were much lower
than in the primes, indicating that MDA, despite its small
molecular size, was not effectively ultrafiltered. MDA can
bind to proteins, which probably prevents its ultrafiltration.
We saw hemolysis during centrifugation in the samples
from FFP prime. Interestingly, when the same RBCs were
used for ALB prime, no hemolysis was seen. It is possible that
these particular RBCs were more susceptible for factors that
could be stronger in FFP prime than in ALB prime. No TRAP
value, lower FRAP value, the presence of vitamin C, a lower
concentration of protein/albumin, and sulfhydryl groups in the
FFP prime can be explanations for the hemolysis.
We used ultrafiltration during the preparation of the
primes in an attempt to decrease the metabolic load from
preserved RBCs and to reduce the prime volume.27 In this
study we showed that ultrafiltration also removes important
low-molecular-weight antioxidants, such as vitamin C and
uric acid. Their concentrations were not changed; however,
the total amount of these antioxidants in the prime decreas-
es. This implies that ultrafiltration during and after CPB
may reduce the amount of important low-molecular-weight
antioxidants in the circulation of the patient. However, we
showed that despite the loss of these low-molecular-weight
antioxidants, the total antioxidant capacity of the prime is
not decreased after ultrafiltration.
In conclusion, we showed that both ALB prime and FFP
prime had no TRAP value. FRAP values were much lower
than the values measured in the undiluted human albumin
solution or in FFP prime. Mannitol did not improve the
antioxidant capacity of the primes. During ultrafiltration,
low-molecular-weight antioxidants were lost into the ultra-
filtrate. Ultrafiltration was not able to decrease the concen-
tration of MDA in the primes. Composition and antioxidant
capacity of prime may substantially affect antioxidant
capacity of neonates undergoing CPB. To emphasize the
marked dilutional changes in antioxidant concentration that
could occur, we compare the normal plasma antioxidant
concentrations in terms of babies and adults with the con-
centrations found in prepared primes (Table 1).28 If ultrafil-
tration is used during the prime preparation, attention has to
be paid to supplementation of antioxidants to the prime after
the use of ultrafiltration.
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